Please assess the completion status of the following clinical trial:

Trial Title: Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Provision of informed consent~2. Male or female ≥18 years of age~3. Histologic or cytologic confirmed diagnosis of small cell lung cancer, either limited or extensive disease at initial presentation is allowed~4. Evidence of progressive disease during or following 1 or 2 prior chemotherapy regimens~   * At least 1 prior regimen must have contained a platinum salt~  * 'Adjuvant therapy' will constitute a prior treatment regimen~  * No more than 2 prior regimens are allowed~5. Measurable disease (only for the phase II portion)~6. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1~7. A minimum life expectancy of 12 weeks~8. Adequate bone marrow, hepatic and renal function as evidenced by:~   * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~  * Platelet count ≥ 100 x 109/L~  * Hemoglobin ≥ 9.0 g/dL~  * Serum bilirubin \< 1.5 x ULN~  * Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT) \< 2.5 x ULN for the reference laboratory or \< 5 x ULN in the presence of liver metastases~  * Serum creatinine \< 1.5 x ULN~9. No 'active' CNS metastases. Prior CNS metastases are allowed, provided adequate palliative therapy has been administered and CNS disease control has been established prior to study entry.~   • A brain MRI scan, ≤ 28 days from day 1, is required~10. Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures and who have a negative serum pregnancy test within 1 week prior to initial study treatment. (See Appendix B)~11. Male patients willing to use adequate contraceptive. (See Appendix B)~12. At least 21 days must have elapsed prior to day 1 cycle 1, from chemotherapy, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for limited palliative radiotherapy, defined as a course of therapy encompassing \< 25% total bone marrow volume and not exceeding 30 Gy.~13. At least 14 days must have elapsed for chemotherapy regimens, biologic, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity.~Exclusion Criteria:~1. Patients who are pregnant or breastfeeding.~2. Active involvement of the Central Nervous System (CNS).~3. Uncontrolled infection or systemic disease.~4. Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.~5. Chemotherapy regimens within the last 21 days (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens, biologic, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity within the last 14 days.~6. No concurrent systemic chemotherapy or anticancer biologic therapy is allowed. Note: Patients on hormonal treatment for breast cancer or prostate cancer may continue on treatment and enter into study.~7. Known hypersensitivity to any components of SC16LD6.5 study drug product.~8. Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor.~9. Psychiatric disorder or social or geographic situation that would preclude study participation.~10. QT interval measurement corrected by Fridericia's formula (QTcF) interval of \>450 msec (males) or \>470 msec (females)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rovalpituzumab tesirine (Type: EXPERIMENTAL): Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).